TOTAL VOLUME:

$134b

24H VOL:

$85,014,378

24H TRANSACTIONS:

2,388,728,490

OPEN INTEREST:

$1,391,695,592

394,774

Markets across

30,069

events

MATCHED EVENTS:

2,615

PLATFORM COVERAGE:

5

Polymarket:

39%

VS.

Kalshi:

61%

BETA
Dashboards
Insights
Indices
Tour
All
Trending
Breaking
New
Ending Soon
Politics
Sports
Crypto
Companies
Elections
Financials
Economics
Other
Entertainment
Science and Technology
Will the FDA approve baxdrostat for hard-to-control hypertension?
kalshi

Will the FDA approve baxdrostat for hard-to-control hypertension?

Volume:
$6,258

Before Jun 1, 2026

 - Kalshi

Before Jun 1, 2026 - Kalshi

1W

News

Positive

Negative

Neutral

Hover marker for details

Vol.

·

Resolved May 18, 2026

Closed: May 18, 4:43 PM EST

kalshi

Kalshi

View
Join Kalshi and score $25 for your first trade.
Outcome
Trade
Chance %
Price
Spread
Liquidity
Volume
24h
7d
Open Interest
Ends in
Result
kalshi

Before Jun 1, 2026

View
100%
Yes 100¢No 0¢
1¢
N/A
$4,115
N/A
N/A
$3,128
1y 3mo
Yes
kalshi

Before Jul 1, 2026

View
100%
Yes 100¢No 0¢
3¢
N/A
$1,834
N/A
N/A
$1,742
1y 3mo
Yes
kalshi

Before Sep 1, 2026

View
100%
Yes 100¢No 0¢
6¢
N/A
$267
N/A
N/A
$267
1y 3mo
Yes
kalshi

Before Aug 1, 2026

View
100%
Yes 100¢No 0¢
5¢
N/A
$42
N/A
N/A
$21
1y 3mo
Yes
kalshi

Before Jan 1, 2027

View
N/A
N/A
4¢
N/A
N/A
N/A
N/A
N/A
1y 3mo
Yes
Total markets: 5

Description

The FDA will make a regulatory decision on whether to approve baxdrostat, a pharmaceutical treatment for hard-to-control hypertension, by a specified deadline in 2026 or early 2027.